Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose.;
London: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. have announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US.
RYALTRIS is approved by the US Food and Drug Administration (USFDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older.
RYALTRIS is the fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose.
"Allergic rhinitis and allergic conjunctivitis are among the most common chronic diseases in the US today, affecting 60 million Americans each year, yet approximately one in seven US adults have reported their nasal allergy symptoms are either poorly controlled or not controlled at all,5 and ocular symptoms are reported to be as severe as nasal symptoms," said Leonard Bielory, M.D. Professor of Medicine, Allergy, Immunology and Ophthalmology at Hackensack Meridian School of Medicine.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.